Clinical Trials Logo

Gastrointestinal Neoplasms clinical trials

View clinical trials related to Gastrointestinal Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06361576 Completed - Clinical trials for Upper Gastrointestinal Cancer

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Start date: September 5, 2023
Phase:
Study type: Observational

The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.

NCT ID: NCT06361563 Completed - Clinical trials for Upper Gastrointestinal Cancer

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Start date: September 5, 2023
Phase:
Study type: Observational

The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.

NCT ID: NCT06159049 Completed - Clinical trials for Gastrointestinal Cancer

Clinical Translation of a Novel FAPI Dimer [68Ga]Ga-LNC1013

Start date: July 21, 2022
Phase:
Study type: Observational [Patient Registry]

Fibroblast activation protein (FAP) emerges as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of current FAP inhibitors (FAPIs), this study presented the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging study were conducted to screen the lead compound with the potential for radionuclide therapy.

NCT ID: NCT06022692 Completed - Clinical trials for Gastrointestinal Tumor

Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours

HEAIS001
Start date: June 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Gastrointestinal tumours (GITs) are the most common and fatal cancers worldwide; 96% of GITs show the microsatellite-stable (MSS)/proficient mismatch repair (pMMR) phenotype, and these tumours have a poor response to immune checkpoint inhibitor (ICI) therapy. Hyperthermia combined with ICI treatment (HIT) has been reported to show a synergistic sensitisation effect in numerous basic studies. This study aimed to validate the effectiveness, safety, and feasibility of water-filtered infrared A radiation (WIRA) whole-body hyperthermia combined with PD-1 inhibitor therapy and evaluate the real-world clinical application prospects of HIT. This open-label single-arm phase 2 clinical trial aimed to enrol advanced GIT patients with the MSS/pMMR phenotype in the East Asian population who had received third-line or higher treatment. The patients were treated with whole-body hyperthermia on days 1 and 8 of each HIT cycle along with administration of tislelizumab 200 mg on day 2 (24 h after the hyperthermia at day 1). The primary outcome was the disease control rate (DCR), while the secondary outcomes were progression-free survival (PFS), overall survival (OS), safety, and improvement in quality of life.

NCT ID: NCT06018246 Completed - Clinical trials for Gastrointestinal Cancer

Nutritional Risk Screening Nutritional Support Gastrointestinal Cancer

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial was to compare the effects of different nutritional support methods based on nutritional risk screening on postoperative nutritional status in patients with gastrointestinal tumors.The main question it aims to answer is that different types of nutrition can improve the nutritional status of patients with different nutritional status;Long-term dietary interventions for patients with poor nutrition can make cancer patients better able to tolerate surgery and chemotherapy and improve their quality of life.The intervention group received nutrition + exercise + psychological intervention upon admission, routine parenteral and enteral nutrition support after operation, and continued nutrition + exercise + psychological intervention after discharge.The control group received routine parenteral nutrition support in the department after surgery, and the patients and their families were given diet education during hospitalization.

NCT ID: NCT05867810 Completed - Nutritional Status Clinical Trials

Nutritional Status Among Upper Gastrointestinal Cancer Patients Upon Admission

RSCH ID-22-012
Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

Cross-sectional study. Data on clinical, anthropometric, biochemical profile and dietary intake Upper Gastrointestinal Cancer Patients upon admission are traced and collected.

NCT ID: NCT05795374 Completed - Clinical trials for Gastrointestinal Cancer

Nutritional and Functional Assessment of Patients Undergoing Surgery Due to Gastrointestinal Cancer (NUFAGI).

NUFAGI
Start date: March 1, 2022
Phase:
Study type: Observational

Several patients that suffer from gastrointestinal (GI) cancer are characterized by malnutrition and impairment of their functional status. The aim of the present study is to evaluate the nutritional condition of patients undergoing surgery due to GI cancer and compare it with their functional status. All consecutive patients with esophageal, gastric, colorectal, hepatocellular, pancreatic and biliary cancer, that underwent a surgical operation will be included. Demographic characteristics, nutritional assessment and anthropometric measurements of the patients will be recorded.

NCT ID: NCT05620537 Completed - Prognosis Clinical Trials

A Novel Nomogram to Predict the Postoperative Overall Survival in Gastrointestinal Cancer Patients

Start date: November 10, 2022
Phase:
Study type: Observational

This multicenter retrospectively observational cohort study was conducted on participants with histologically confirmed gastric and colorectal cancer who underwent radical surgery in 11 medical centers in China from August 1, 2015, to June 31, 2018. Baseline clinicopathologic data and nutritional status assessments including Nutrition Risk Screening 2002 (NRS 2002) score and Patient-generated Subjective Global Assessment (PG-SGA) rating were collected. Variables will be screened using the least absolute shrinkage and selection operator (LASSO) regression model and Cox regression analysis. Internal and external validations will be performed via the receiver operating curve (ROC), the area under the curve (AUC), the concordance index (C-index), calibration plots, decision curve analysis (DCA), and Five folds cross-validation by 200 times.

NCT ID: NCT05583292 Completed - Clinical trials for Gastrointestinal Tumours

Mortality Predictions With Scorring Indices in Gastrointestinal Tumours

Start date: February 11, 2023
Phase:
Study type: Observational

The ASA-PS, SORT and Sarcopenia scores of the patients who will undergo surgery for a gastrointestinal tumor will be recorded. Thus, the correlation between preoperative indices and mortality/morbidity will be evaluated.

NCT ID: NCT05396781 Completed - Clinical trials for Suspected or Known Squamous Cell Neoplasia

Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening

Start date: January 13, 2022
Phase: Phase 2
Study type: Interventional

The investigators have a current trial in China and the US which provides significant support for the safety, cost-effectiveness, accuracy and efficiency of a high resolution microendoscope (HRME)-guided approach in the hands of experienced clinicians. To improve functionality, portability and broader use of this device by non-experts, the investigators recently developed a prototype marHRME platform with an automated, augmented reality (AR)-interpretation that provides an overlaid endoscopic + micro-endoscopic view, facilitating diagnosis and biopsy targeting.